PGPascal J. Goldschmidt-Clermont

Pascal J. Goldschmidt-Clermont

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pascal J. Goldschmidt-Clermont has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Chunming Dong

    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina

    4 shared publications
  • Tao Wang

    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA

    2 shared publications
  • Woohyun Yoon

    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710

    2 shared publications
  • Barbara White

    Division of Cardiology, Duke University Medical Center, 7504 Duke Hospital North, Box 3845, Durham, NC 27710; †Heart and Lung Institute, Ohio State University, Columbus, OH 43210; ‡Division of Cellular Biochemistry, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands; §Baltimore Veterans Affairs Medical Center, University of Maryland, Baltimore, MD 21201; and ¶Division of Rheumatology, Johns Hopkins University, Baltimore, MD 21205

    1 shared publication
  • Douglas W. Lorsordo

    From Duke University Medical Center, Department of Medicine, Cardiology Division, Durham, NC (P.J.G.-C., G.K.W.L., V.J.D.); Brigham and Women’s Hospital, Cardiovascular Division, and Harvard Medical School, Boston, Mass (M.A.C.); Division of Cardiovascular Research, St Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, Mass (D.W.L.); and Division of Heart and Vascular Diseases, National Heart, Lung and Blood Institute, Bethesda, Md (M.W.).

    1 shared publication
  • Edward E. Herderick

    From the Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC (T.W., C.D., S.S.V., P.J.G.C.); Dorothy M. Davis Heart and Lung Research Institute, Department of Biomedical Engineering, The Ohio State University, Columbus, Ohio (E.E.H., N.I.M., R.E.M.); Genetic Therapy, Inc, Gaithersburg, Md (S.C.S., J.M.N.); and the Transplantation Department, Novartis, Basel, Switzerland (N.R.M.).

    1 shared publication

Latest Publications

  • Open Access

    Atherosclerosis 2005

    by Pascal J. Goldschmidt-Clermont, Mark A. Creager, Douglas W. Lorsordo, Gregory K.W. Lam, Momtaz Wassef, Victor J. Dzau

    A therosclerosis is an inflammatory process that selectively affects arteries and is highly prevalent in both women and men. Thrombo-occlusive complications of atherosclerosis, including stroke and myocardial infarction, are major causes of morbidity and mortality. Senescence of the arterial tree is a biological process that follows a natural course that can be accelerated by the combined injury of multiple risk factors. A repair capacity that is intrinsic to the organism can counteract the natural time-and risk factordependent obsolescence of arteries. The failure of this repair process is intimately linked to atherosclerotic inflammation and lesion formation. Recruitment and targeting of bone marrow-derived progenitor vascular cells, and probably vascular progenitors originating in other tissues, that have an intrinsic capacity for repair of the vascular wall represent a promising area for research and development. This review focuses on recent discoveries relevant to vascular progenitor cells and others that are likely to influence atherosclerosis research. It highlights the exciting recent findings that demonstrate the vital role of vascular progenitor cells in the homeostasis of the vessel wall and the mitigation of atherosclerosis. In the context of atherosclerosis, this review also discusses the relevance of this paradigm to pharmacological treatment of atherosclerosis and the process of aging.


  • Endothelial Progenitor Obsolescence and Atherosclerotic Inflammation

    by Chunming Dong, Lawrence E. Crawford, Pascal J. Goldschmidt-Clermont


  • On the Memory of a Chronic Illness

    by Pascal J. Goldschmidt-Clermont, Eric D. Peterson

    The elderly are particularly susceptible to disease, yet the biological mechanisms that bring about this susceptibility remain unclear. Using atherosclerosis as a model chronic illness, we review how recent studies of bone marrow-derived vascular repair systems in mice and humans provide new insights into the causes and potential cures for age-related illness. Organisms are born with a finite capacity for stem cell-mediated repair after chronic exposure to tissue injury. Once that capacity is exhausted, a cycle of pathological inflammation ensues and leads to overt disease manifestations. Augmentation of stem cell-mediated repair systems may provide a novel means of treating or preventing many age-related illnesses.


  • Overexpression of Soluble Fas Attenuates Transplant Arteriosclerosis in Rat Aortic Allografts

    by Tao Wang, Chunming Dong, Susan C. Stevenson, Edward E. Herderick, Jennifer Marshall-Neff, Sanjay S. Vasudevan, Nicanor I. Moldovan, Robert E. Michler, N. Rao Movva, Pascal J. Goldschmidt-Clermont

    Background— The killing of vascular cells by activated macrophages is an important step in the process of destabilization of the arterial wall. The death receptor Fas is implicated in vascular cell death. Hence, we extended our studies in a rat aortic allograft model, using adenovirus-mediated overexpression of soluble Fas (sFas) to block Fas binding to Fas ligand (Fas-L). The contribution of Fas to vascular cell injury and consequent transplant arteriosclerosis was investigated. Methods and Results— Activated monocytes in the presence of macrophage colony-stimulating factor induce endothelial cell apoptosis in vitro, which was significantly inhibited by adenovirus-mediated sFas overexpression. Next, donor rat abdominal aortas were either untreated or transduced with adenoviruses encoding (1) rat soluble Fas (Ad3rsFas), (2) no insert (Ad3Null), and (3) β-galactosidase (Ad3nBg). A total of 175 aortic grafts were harvested 2 to 90 days after transplantation. Vascular cell apoptosis and CD45+ cell infiltration were significantly reduced in Ad3rsFas-transduced aortas, as compared with control allografts. Moreover, the control allografts developed marked intimal thickening, whereas Ad3rsFas-transduced allografts had significantly less neointima until the 90-day time point. Conclusions— sFas overexpression protects the integrity of the vessel wall from immune injury and attenuates transplant arteriosclerosis.


  • Open Access

    DNA Methylation and Atherosclerosis

    by Chunming Dong, Woohyun Yoon, Pascal J. Goldschmidt-Clermont

    DNA methylation is a major epigenetic modification of the genome that has the potential to silence gene expression. Recently, the role of epigenetic alteration as a distinct and crucial mechanism to regulate genes governing cell proliferation in atherosclerosis has emerged. Aberrant methylation is related to aging, and, because it affects a large number of CpG islands, age-related methylation may be an important contributor to increased atherosclerosis among older individuals by upregulating atherosclerosis-susceptible genes and downregulating atherosclerosis-protective genes. Further dissection of epigenetic alterations in atherosclerosis and aging will lead to the identification of novel epigenetic modifiers and improved diagnosis and treatment for atherosclerosis-related diseases.


  • Retracted
    Open Access

    RETRACTED: Deficient Smad7 expression: A putative molecular defect in scleroderma

    by Chunming Dong, Shoukang Zhu, Tao Wang, Woohyun Yoon, Zhiru Li, Rene J. Alvarez, Peter Ten Dijke, Barbara White, Fredrick M. Wigley, Pascal J. Goldschmidt-Clermont

    Scleroderma is a chronic systemic disease that leads to fibrosis of affected organs. Transforming growth factor (TGF) β has been implicated in the pathogenesis of scleroderma. Smad proteins are signaling transducers downstream from TGF-β receptors. Three families of Smads have been identified: ( i ) receptor-regulated Smad2 and -3 (R-Smads); ( ii ) common partner Smad4 (Co-Smad); and ( iii ) inhibitory Smad6 and -7 (I-Smads, part of a negative feedback loop). We have investigated the signaling components for the TGF-β pathway and TGF-β activity in scleroderma lesions in vivo and in scleroderma fibroblasts in vitro . Basal level and TGF-β-inducible expression of Smad7 are selectively decreased, whereas Smad3 expression is increased both in scleroderma skin and in explanted scleroderma fibroblasts in culture. TGF-β signaling events, including phosphorylation of Smad2 and -3, and transcription of the PAI-1 gene are increased in scleroderma fibroblasts, relative to normal fibroblasts. In vitro adenoviral gene transfer with Smad7 restores normal TGF-β signaling in scleroderma fibroblasts. These results suggest that alterations in the Smad pathway, including marked Smad7 deficiency and Smad3 up-regulation, may be responsible for TGF-β hyperresponsiveness observed in scleroderma.